Brief: Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial

Septerna

18/02/2025 14:55

Feb 18 (Reuters) - Septerna Inc  SEPN.O :
    * SEPTERNA ANNOUNCES DISCONTINUATION OF SEP-786 PHASE 1
CLINICAL
TRIAL AND PLANS TO ADVANCE NEXT-GENERATION ORAL SMALL MOLECULE
PTH1R AGONIST
    * SEPTERNA INC - DECISION FOLLOWS SEVERE EVENTS OF ELEVATED
BILIRUBIN IN PHASE 1 TRIAL
    * SEPTERNA INC - NO LIVER INJURY OR SERIOUS ADVERSE EVENTS
IN
PHASE 1 TRIAL
    * SEPTERNA INC - EXPECTS CASH POSITION TO SUPPORT OPERATIONS
INTO
2027
    * SEPTERNA INC: ADVANCING MULTIPLE NEXT-GENERATION PTH1R
AGONISTS
WITH DISTINCT AND UNRELATED CHEMICAL STRUCTURES RELATIVE TO
SEP-786

Source text:  ID:nGNXbKM318 
Further company coverage:  SEPN.O 

 ((reuters.briefs@thomsonreuters.com;))